Protara Therapeutics Shares Drop After Interim ADVANCED-2 Data Is Released
Protara Therapeutics saw its stock decline following the publication of interim results from its Phase 2 ADVANCED-2 study of TARA-002 in patients with high-risk Non-Muscle Invasive Bladder Cancer. The data cover evaluable participants in both BCG-Unresponsive and BCG-Naïve cohorts, report favorable safety signals, and set expectations for registrat…